Janux Therapeutics (JANX) EBITDA Margin (2021 - 2026)
Janux Therapeutics (JANX) reported EBITDA Margin of 752.77% for Q1 2026, down 220.36% quarter-over-quarter from 234.98% in Q3 2025.
Janux Therapeutics (JANX) EBITDA Margin (2021 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has 6 years of EBITDA Margin data on file, last reported at 752.77% in Q1 2026.
- EBITDA Margin for Q1 2026 came in at 752.77%, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 856.75% (down 6989.0% YoY), and the FY2025 annual result was 1114.72%, down 47724.0% from the prior year.
- EBITDA Margin fell to 752.77% in Q1 2026 per JANX's latest filing, from 234.98% in the prior quarter.
- Over five years, EBITDA Margin peaked at 79.25% in Q2 2024 and troughed at 4239.64% in Q3 2024.
- A 5-year average of 1007.61% and a median of 752.77% in 2026 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2024 and 2025: EBITDA Margin sank 377547 bps in 2024, then soared 400466 bps in 2025.
- A 5-year view of EBITDA Margin shows it stood at 538.59% in 2022, then climbed by 25 bps to 403.01% in 2023, then slumped by 952 bps to 4239.64% in 2024, then soared by 94 bps to 234.98% in 2025, then plunged by 220 bps to 752.77% in 2026.
- Business Quant data shows JANX's EBITDA Margin at 752.77% in Q1 2026, 234.98% in Q3 2025, and 4239.64% in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Janux Therapeutics | 892.99 Mn | 892.99 Mn | - | -752.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -752.77% |
| Sep 30, 2025 | -234.98% |
| Sep 30, 2024 | -4,239.64% |
| Jun 30, 2024 | -79.25% |
| Mar 31, 2024 | -1,273.88% |
| Dec 31, 2023 | -403.01% |
| Sep 30, 2023 | -464.16% |
| Jun 30, 2023 | -1,686.75% |
| Mar 31, 2023 | -813.62% |
| Dec 31, 2022 | -538.59% |
| Sep 30, 2022 | -941.31% |
| Jun 30, 2022 | -728.46% |
| Mar 31, 2022 | -942.54% |
| Dec 31, 2021 | -848.39% |
| Sep 30, 2021 | -928.30% |
| Jun 30, 2021 | -1,284.02% |
| Mar 31, 2021 | -601.05% |